When the SURMOUNT-1 trial results came out showing 22.5% average weight loss at 72 weeks, the weight loss world had to recalibrate. That number — almost a quarter of body weight in people with obesity — was unprecedented for a non-surgical intervention. Tirzepatide had arrived.
It's been a few years since then. Tirzepatide is now commercially available as Mounjaro (diabetes) and Zepbound (obesity), the clinical picture has filled in considerably, and research peptide suppliers have made it accessible outside the prescription system. Here's what you actually need to know.
🔑 Key Takeaways
- Tirzepatide is a dual GIP + GLP-1 receptor agonist — the first approved drug to target both pathways simultaneously
- Average weight loss at 72 weeks in SURMOUNT-1: 20.9% (10mg) to 22.5% (15mg) — significantly better than semaglutide alone
- Sold as Mounjaro for type 2 diabetes and Zepbound for obesity management
- Official dosing starts at 2.5mg and escalates every 4 weeks up to 15mg maximum
- GI side effects (nausea, diarrhea) are common early, especially during dose escalation — they typically settle down
- Retatrutide, a newer triple agonist, is showing even stronger results (~24% weight loss) in trials
What Is Tirzepatide?
Tirzepatide is a synthetic peptide that mimics two naturally occurring gut hormones simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both are released after you eat. Both tell your body to increase insulin, decrease glucagon, and — critically for weight loss — signal your brain that you're full.
GLP-1 is the mechanism behind semaglutide (Ozempic/Wegovy). Tirzepatide does all of that, plus activates GIP receptors on top. The dual action is why its results consistently beat semaglutide head-to-head.
It's a once-weekly subcutaneous injection. Lilly produces it; it comes in an auto-injector pen in a few fixed dose strengths.
How It Works — The Simple Version
When you eat, your gut releases GIP and GLP-1. These hormones:
- Tell your pancreas to release more insulin — but only when blood sugar is elevated, which is why tirzepatide doesn't cause hypoglycemia in most people the way older diabetes drugs do
- Block glucagon release — glucagon is the hormone that tells your liver to dump more sugar into the bloodstream; blocking it keeps blood sugar more stable
- Slow gastric emptying — food moves more slowly from your stomach to your intestines, which keeps you feeling full longer
- Signal the hypothalamus — this is the weight loss mechanism: your brain receives persistent satiety signals, which reduces hunger and spontaneous calorie intake
The GIP component adds a second angle. It appears to enhance the GLP-1 signaling at both the pancreatic and brain levels, and may have independent effects on fat tissue metabolism. Exactly how these two pathways work together to produce tirzepatide's outsized weight loss is still being studied — but the clinical result is clear.
What Results Look Like
The SURMOUNT-1 trial (published in NEJM, 2022) enrolled over 2,500 adults with obesity. After 72 weeks:
- 5mg dose: 16% average weight loss
- 10mg dose: 21.4% average weight loss
- 15mg dose: 22.5% average weight loss
For context: semaglutide 2.4mg (Wegovy) in the STEP-1 trial produced about 14.9% weight loss at 68 weeks. Tirzepatide beats that at every dose above 5mg.
Beyond the scale: participants also saw improvements in waist circumference, blood pressure, insulin sensitivity, and lipid profiles. The drug appears to be doing more than just cutting calories — there seem to be direct metabolic effects as well.
Side Effects Overview
The most common side effects are GI-related and front-loaded to the early weeks of treatment and dose escalation periods:
- Nausea (~30–40% of users, usually mild to moderate)
- Diarrhea (~20–30%)
- Vomiting (~15–20%)
- Constipation (~10–15%)
- Decreased appetite (technically the desired effect, but occasionally extreme)
Most GI effects diminish after the dose stabilizes. The strategy of slow, gradual escalation exists specifically to minimize these. People who jump doses or skip the titration schedule get hit harder.
Rare but more serious concerns include pancreatitis, gallbladder issues (tirzepatide increases gallstone risk), and the theoretical thyroid concern (C-cell tumors seen in rodents — not in humans, but the class warning exists on the label).
Dosage Titration Schedule
This is the official protocol from the FDA-approved prescribing information. The slow escalation exists to reduce GI side effects — skipping ahead almost always means more nausea and vomiting.
| Weeks | Dose | Injections | Notes |
|---|---|---|---|
| 1–4 | 2.5mg | Once weekly | Starting dose — not a therapeutic dose, just tolerance building |
| 5–8 | 5mg | Once weekly | First dose with meaningful clinical effect for most people |
| 9–12 | 7.5mg | Once weekly | Many people see their best tolerance/efficacy balance here |
| 13–16 | 10mg | Once weekly | Strong efficacy — ~21% weight loss in trials at this dose |
| 17–20 | 12.5mg | Once weekly | Optional step for those titrating to max |
| 21+ | 15mg | Once weekly | Maximum approved dose — highest efficacy, highest GI burden |
💡 Pro Tip
The 4-week intervals are minimums. If GI side effects are significant at a new dose, staying at that dose for 8 weeks before escalating is completely reasonable. Most prescribers will support this — the goal is finding your sustainable maintenance dose, not reaching 15mg as fast as possible.
Tirzepatide vs Semaglutide
| Feature | Tirzepatide (Zepbound/Mounjaro) | Semaglutide (Wegovy/Ozempic) |
|---|---|---|
| Mechanism | GIP + GLP-1 dual agonist | GLP-1 agonist only |
| Avg. weight loss | 20–22.5% (72 weeks) | ~14–15% (68 weeks) |
| Dosing | Once weekly, 2.5–15mg | Once weekly, 0.25–2.4mg |
| Half-life | ~5 days | ~7 days |
| FDA approval (obesity) | Yes (Zepbound, 2023) | Yes (Wegovy, 2021) |
| Brand price/month | ~$1,000–$1,200 | ~$1,300–$1,500 |
| GI side effects | Similar — manageable with titration | Similar |
The head-to-head comparison (SURPASS-6) confirms what the individual trial data already suggested: tirzepatide produces more weight loss than semaglutide at comparable time points.
Tirzepatide vs Retatrutide
Retatrutide adds a third receptor target — the glucagon receptor — on top of tirzepatide's dual mechanism. The glucagon pathway drives additional fat oxidation and appears to boost overall energy expenditure beyond what GIP/GLP-1 alone achieve.
In the Phase 2 trial published in NEJM (Jastreboff et al., 2023), retatrutide produced 24.2% body weight reduction at 48 weeks at the highest dose. Tirzepatide at a comparable time point sits around 18–20%.
Retatrutide is not yet FDA-approved (it's in Phase 3 trials as of 2026), which means it's only available through research peptide channels for now. But the efficacy data is compelling enough that anyone evaluating tirzepatide should at least be aware it exists.
How to Get Tirzepatide
Route 1: Prescription
The cleanest option. Telehealth platforms (Ro, Hims & Hers, Calibrate) can prescribe tirzepatide online. You need a BMI qualifying for obesity treatment or a type 2 diabetes diagnosis. Insurance coverage for Zepbound (obesity) has improved but remains inconsistent. Mounjaro (diabetes) has somewhat better coverage.
Brand price without insurance: roughly $1,000–$1,200/month.
Route 2: Research Peptide Suppliers
For people outside the prescription system or unable to afford brand pricing, research peptide suppliers carry tirzepatide in lyophilized powder form with COAs. Quality varies — independent third-party testing is the only meaningful differentiator.
Ascension Peptides carries tirzepatide as T-10 (10mg) with independent COA verification.
🔬 Where to Source Tirzepatide for Research
Ascension Peptides' T-10 (Tirzepatide 10mg) comes with third-party COA documentation. It's one of the more consistently stocked tirzepatide options from a US domestic supplier.